title: PHARMAC responds on Herceptin assumptions and decisions.
authors.forename: Scott
authors.initials: S
authors.lastname: Metcalfe
authors.forename: Jackie
authors.initials: J
authors.lastname: Evans
mesh_terms: D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D004345:Drug Industry / Q000191:economics*; D005260:Female; D006801:Humans; D009313:National Health Programs / Q000191:economics*; D009520:New Zealand; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D000068878:Trastuzumab